By Amy Norton 

HealthDay Reporter

THURSDAY, Might 11, 2023 (HealthDay Information) — A “peanut patch” worn on the pores and skin could assist shield toddlers who’ve probably life-threatening peanut allergic reactions, a brand new medical trial reveals.

The patch is a type of immunotherapy, which implies it exposes peanut-allergic kids to tiny bits of peanut protein over time — with the purpose of coaching the immune system to higher tolerate it.

Within the trial, researchers discovered that of toddlers who wore the peanut patch each day for a yr, two-thirds confirmed a big discount of their sensitivity to peanut protein: They had been capable of eat the equal of 1 to 4 peanuts with out struggling an allergic response.

Whereas which may sound like peanuts, specialists mentioned that degree of tolerance is vital.

The purpose of immunotherapy is to stop a extreme response ought to a baby by accident ingest a small quantity of peanut, mentioned Dr. Alkis Togias, of the U.S. Nationwide Institute of Allergy and Infectious Illnesses.

“This can be a constructive research,” mentioned Togias, who wrote an editorial printed with the findings on Might 10 within the New England Journal of Medication.

The patch examined within the trial, referred to as Viaskin, is being developed by French biotech firm DVB Applied sciences, which funded the analysis. It’s not but accepted by the U.S. Meals and Drug Administration.

If it does win approval, Togias mentioned, “I feel that will solely be a superb factor.”

An estimated 2% of U.S. kids are allergic to peanuts, and for many the allergy continues into maturity. That makes it the most typical meals allergy amongst children, and the third-most widespread amongst adults, in accordance with the nonprofit Meals Allergy Analysis and Schooling (FARE).

Folks with peanut allergy can endure reactions, generally extreme, from ingesting even a small quantity of the meals — the portions which are generally lurking in processed or ready meals. In order that they (or their mother and father) must studiously learn meals labels and take different precautions to keep away from peanut publicity.

However that is not straightforward, Togias mentioned, and accidents occur.

So far as therapy, there may be an oral type of immunotherapy accepted by the U.S. Meals and Drug Administration for peanut allergy, referred to as Palforzia. It is a peanut flour product that may be blended into meals, like applesauce. Nevertheless it’s solely accepted for youngsters ages 4 and older.

“There are presently no FDA-approved therapy choices for toddlers underneath 4 years outdated,” mentioned Dr. Matthew Greenhawt, the lead researcher on the brand new trial.

Oral immunotherapy is underneath research for toddlers with peanut allergy. However Greenhawt mentioned it is all the time good to have a number of choices on the desk.

“What works for one household could not work for one more,” he mentioned.

Plus, the patch method could have fewer unwanted side effects, in accordance with Greenhawt, a professor of pediatrics at Youngsters’s Hospital Colorado/College of Colorado Faculty of Medication.

The patch, he mentioned, “takes benefit” of the truth that the pores and skin is the physique’s largest immune system organ. Meaning a smaller dose of peanut protein can be utilized, serving to to skirt the systemic unwanted side effects generally attributable to oral immunotherapy — corresponding to upset abdomen, throat irritation and shortness of breath.

These varieties of issues not often come up with the patch, mentioned Greenhawt, who additionally serves as a medical advisor to DBV Applied sciences.

The trial concerned 362 toddlers, ages 1 to three, who had been randomly assigned to put on both the peanut patch or a placebo (inactive) patch each day for a yr. Total, 67% of kids on the actual therapy met the trial’s finish purpose: Their immune tolerance was constructed as much as the purpose that they might ingest the equal of 1 to 4 peanuts with out an allergic response.

That in contrast with 33% of kids within the placebo group.

Pores and skin rash was the most typical facet impact with the peanut patch, whereas slightly below 2% of toddlers developed systemic signs that had been judged “delicate to average.”

How would that stack up towards peanut powder?

It is laborious to guage, Togias mentioned, as a result of no trial has in contrast the approaches face to face.

However he pointed to a trial printed final yr that examined oral immunotherapy for 1- to 3-year-olds with peanut allergy. The findings, Togias mentioned, recommend that the oral method could have stronger results in desensitizing the immune system.

Alternatively, he added, the pores and skin patch could also be safer.

One bigger-picture query round immunotherapy for peanut allergy, Togias mentioned, is whether or not there’s a level at which it may be stopped. Palforzia is taken each day indefinitely, to take care of the immune system’s tolerance for peanut.

Greenhawt mentioned the peanut patch can be designed for each day use, and trials to this point (together with one in every of older kids) have adopted sufferers for as much as three years of use.

Jennifer Bufford, vice chairman of medical operations at FARE, agreed that having a number of varieties of immunotherapy could be good for households.

Bufford additionally famous that many individuals with peanut allergy are allergic to different meals, too. “Will probably be fascinating to see if epicutaneous [via the skin] desensitization will be achieved for different widespread meals allergens,” she mentioned.

Whereas there may be constructive information on the therapy entrance, Togias pressured one other level: Peanut allergic reactions will also be prevented, by introducing peanut merchandise into infants’ diets as soon as they begin on strong meals.

Extra data

FARE has extra on peanut allergy.


SOURCES: Matthew Greenhawt, MD, MBA, MSc, professor, pediatrics, part of allergy and immunology, Youngsters’s Hospital Colorado, College of Colorado Faculty of Medication, Aurora; Alkis Togias, MD, department chief, allergy, bronchial asthma and airway biology department, U.S. Nationwide Institute of Allergy and Infectious Illnesses, Bethesda, Md.; Jennifer Bufford, MS, vice chairman, medical operations, Meals Allergy Analysis and Schooling, McLean, Va.; New England Journal of Medication, Might 11, 2023

Supply hyperlink